Allergic rhinitis
Conditions
Interventions
Placebo group:On the basis of conventional treatment, oral administration of placebo was given.
Probiotic group:On the basis of conventional treatment, oral administration of probiotic was given.
Sponsors
Jingdezhen Second People’s Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 3 - 16 years old. Gender: Open to both males and females. 2.Be able to accept and cooperate in completing the relevant examinations for the research; 3.Voluntary participation. One can either conduct the research procedures independently or under the supervision of a guardian, and sign the informed consent form. 4.Complies with the AR diagnostic criteria established in the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in Children (Revised Edition 2022)"; 5.Symptoms: Two or more symptoms occur: sneezing, watery nasal discharge, nasal itching and nasal congestion. The symptoms persist or accumulate for more than one day, and may also be accompanied by eye symptoms such as itching, watering eyes and redness. 6.Physical symptoms: The nasal mucosa appears pale and swollen, with watery discharge.
Exclusion criteria
Exclusion criteria: 1.During the 1-month period before random grouping, various types of antibiotics had been used. 2.Within one week prior to random grouping, those who had consumed probiotic foods and/or beverages and/or health supplements (such as yogurt); 3.Comorbid allergic, inflammatory or structural respiratory system diseases: diagnosed with concurrent allergic asthma, tuberculosis, nasal polyps, severe deviation of the nasal septum, sinusitis or otitis media; 4.Significant systemic or gastrointestinal disorders: Presence of severe systemic diseases, malignant tumors, congenital genetic or immune deficiency disorders, or severe gastrointestinal disorders (such as severe diarrhea, inflammatory bowel disease); 5.Metabolism and chronic diseases: Diagnosis of metabolic syndrome, including obesity, dyslipidemia, hypertension or diabetes; 6.There is an active respiratory infection or other acute illness, which may cause confusion in the assessment of nasal allergy symptoms at the time of enrollment or in the research results. 7.Non-compliance with the protocol and other reasons: Known allergies to any component in the research product; inability to follow the research protocol or other intervention measures that may affect the results; or due to personal reasons or as determined by the researcher to be unsuitable to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with nasal inflammation under control; | — |
Secondary
| Measure | Time frame |
|---|---|
| RQLQ score and RCAT compliance rate;Changes in serum levels of IgE, IL-4, IL-10, and IFN-?;Gut microbiota; | — |
Countries
China
Contacts
Public ContactXuewei Lei
Jingdezhen Second People’s Hospital
Outcome results
None listed